Imperagen Secures £5 Million Seed Round to Revolutionize Enzyme Engineering
Biotech startup Imperagen announced on Thursday that it has raised £5 million ($6.7 million) in a seed funding round led by PXN Ventures, with additional backing from IQ Capital and Northern Gritstone. Founded in 2021 by scientists from the Manchester Institute of Biotechnology—Dr. Andrew Currin, Dr. Tim Eyes, and Dr. Andy Almond—the company spun out of the university with the goal of transforming how enzymes are engineered.
Imperagen’s mission centers on accelerating enzyme engineering by moving away from the traditional, slow, and costly trial-and-error methods. Currently, developing enzyme variants depends heavily on physical experimentation, which can take months or even years. By contrast, Imperagen aims to make this process faster, more efficient, and significantly less expensive, thereby unlocking new possibilities across various industries.
Three Core Technologies Driving Innovation
At the heart of Imperagen’s approach are three integrated technologies designed to redefine enzyme engineering. First, the company employs quantum physics-based simulations to predict enzyme behavior. Unlike conventional lab-based mutation testing, this computational method can explore millions of potential mutations rapidly, using advanced quantum models. This capability offers a far deeper understanding of enzyme variants, reducing dependence on physical experiments.
Second, Imperagen leverages custom artificial intelligence (AI) models trained specifically on enzyme-related challenges. These AI models translate the quantum simulation data into actionable insights, enabling more accurate prediction of enzyme functionality and stability.
Finally, the company utilizes robotics and automation to generate experimental data, which feeds back into the AI in a closed-loop system known as closed-loop simulation. This iterative process continuously refines the models, improving accuracy and speeding up the discovery cycle.
Wider Industry Impact and Sustainability Potential
Enzymes play a critical role in numerous sectors, especially pharmaceuticals, where they are essential for drug development. By accelerating enzyme engineering, Imperagen hopes to shorten drug discovery timelines and enhance efficiency, which can have a cascading positive impact on healthcare and beyond.
Beyond pharmaceuticals, enzymes are vital in industries such as food production, biofuels, and agriculture. Experts in sustainability are also turning to enzymes—and the AI technologies surrounding them—to promote greener industrial manufacturing processes. According to the World Economic Forum, enzymatic technology holds promise for more sustainable materials production and manufacturing.
Imperagen joins a growing field of innovative startups, including Biomatter, Cradle Bio, and Absci, all working to advance enzyme engineering through cutting-edge technology.
New Leadership to Scale AI and Industrial Partnerships
Alongside the funding announcement, Imperagen revealed that Guy Levy-Yurista has been appointed CEO. Speaking to TechCrunch, Levy-Yurista emphasized the limitations of current enzyme engineering methods, noting that many AI-powered technologies still struggle to deliver reliable results at an industrial scale.
“Imperagen’s technology aims to make enzyme development faster, more reliable, and more commercially accessible, helping companies bring better bio-based products to market without the long timelines and uncertainty that have traditionally held the field back,” Levy-Yurista explained.
Levy-Yurista brings extensive experience in AI, life sciences, and enterprise technology. While the founding scientists remain actively involved, his role focuses on developing a vertical AI infrastructure tailored for biocatalysis—the acceleration of chemical reactions using natural catalysts like enzymes—and expanding the company’s AI strategy, commercial models, and industrial partnerships.
Future Growth and Commercial Ambitions
Imperagen has now raised a total of £8.5 million ($11.42 million) to date. The latest investment will be directed toward hiring more AI specialists, enhancing research and development capabilities, expanding experimental lab infrastructure, and building a go-to-market function over the next two years.
Looking ahead, Levy-Yurista envisions a future where engineered enzymes enable industries to produce cleaner, safer, and higher-quality products. “Ultimately, Imperagen hopes wider use of engineered enzymes will help industries reliably produce products that are better for people and the planet, while also making commercial sense for the companies that adopt them,” he said.
